Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation

被引：0
|
作者：
Dhanashree Ratra
Krishnakanta Roy
Sneha Giridhar
Sushant Madaan
机构：
[1] Medical Research Foundation,Department of Vitreoretinal Diseases
[2] Sankara Nethralaya,undefined
来源：
Ophthalmology and Therapy | 2022年 / 11卷
关键词：
Anti VEGF; Biosimilar; Comparison with bevacizumab; DME; nAMD; Ranibizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：135 / 149
页数：14
相关论文
共 50 条
  • [31] Real-World Canadian Study to Compare the Syringe Preparation Time for Ranibizumab Prefilled Syringe versus Ranibizumab and Aflibercept Vial
    Giunta, Michel
    Lalonde, Laurent
    Cordahi, Ghassan
    Saurel, Patrick
    Scarino, Andrea
    OPHTHALMOLOGICA, 2016, 236 : 7 - 7
  • [32] Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity
    Ceylan, Osman Melih
    Dikci, Seyhan
    Genc, Oguzhan
    Yilmaz, Turgut
    ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2016, 79 (04) : 279 - 279
  • [33] Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity
    Erol, Muhammet Kazim
    Coban, Deniz Turgut
    Sari, Esin Sogutlu
    Bilgin, Ahmet Burak
    Dogan, Berna
    Ozdemir, Ozdemir
    Tunay, Zuhal Ozen
    ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2015, 78 (06) : 340 - 343
  • [34] Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment
    Suren, Elcin
    Ozkaya, Dilek
    Cetinkayan, Ersan
    Kalayci, Mustafa
    Yigit, Kenan
    Kucuk, Mehmet Fatih
    Erol, Muhammet Kazim
    INTERNATIONAL OPHTHALMOLOGY, 2022, 42 (06) : 1905 - 1913
  • [35] Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment
    Elçin Süren
    Dilek Özkaya
    Ersan Çetinkaya
    Mustafa Kalaycı
    Kenan Yiğit
    Mehmet Fatih Kücük
    Muhammet Kazim Erol
    International Ophthalmology, 2022, 42 : 1905 - 1913
  • [36] An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study
    Eldem, Bora
    Lai, Timothy Y. Y.
    Ngah, Nor Fariza
    Vote, Brendan
    Yu, Hyeong Gon
    Fabre, Alban
    Backer, Arthur
    Clunas, Nathan J.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2018, 256 (05) : 963 - 973
  • [37] Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study
    Callizo, Josep
    Ziemssen, Focke
    Bertelmann, Thomas
    Feltgen, Nicolas
    Voegeler, Jessica
    Koch, Mirja
    Eter, Nicole
    Liakopoulos, Sandra
    Schmitz-Valckenberg, Steffen
    Spital, Georg
    CLINICAL OPHTHALMOLOGY, 2019, 13 : 2167 - 2179
  • [38] An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study
    Bora Eldem
    Timothy Y. Y. Lai
    Nor Fariza Ngah
    Brendan Vote
    Hyeong Gon Yu
    Alban Fabre
    Arthur Backer
    Nathan J. Clunas
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256 : 963 - 973
  • [39] Real-World Treatment Patterns and Vision Outcomes with Ranibizumab for Diabetic Macular Edema
    Naujokaitis, Tadas
    Balciuniene, Vilma Jurate
    JOURNAL OF OPHTHALMOLOGY, 2021, 2021
  • [40] Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study)
    Sharma, Ashish
    Kumar, Nilesh
    Parachuri, Nikulaa
    Bandello, Francesco
    Kuppermann, Baruch D.
    Loewenstein, Anat
    EYE, 2022, 36 (05) : 1106 - 1107
12345